Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis

Canadian Journal of Gastroenterology

Volumn 14, Issue 1, 2000, Pages 33-39

  Jones, E Anthony ^a   Bergasa, Nora ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Cholestasis; Endogenous opioids; Ondansetron; Opiate antagonists; Pruritus

Indexed keywords

ANDROGEN; ANION EXCHANGE RESIN; LIDOCAINE; MONOXERUTIN; MORPHINE; NALMEFENE; NALOXONE; NALTREXONE; ONDANSETRON; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR; RIFAMPICIN;

CHOLESTASIS; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LIVER TRANSPLANTATION; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; REVIEW; SCRATCHING; SEROTONINERGIC SYSTEM;

EID: 0033975520     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/747495     Document Type: Review

References (52)

1. Chia SC, Bergasa NV, Kleiner DE, Goodman Z, Hoofnagle JH, DiBisceglie AM. Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci 1998;43:2177-83.
2. Sherlock S, Dooley J. Cholestasis. In: Diseases of the Liver and Biliary System, 10th edn. Oxford: Blackwell Scientific, 1997:217-37.
3. McCormack HM, de L'Home DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med 1988;18:1007-19.
4. Talbot TL, Schmitt JM, Bergasa NV, Jones EA, Walker EC. Application of piezo film technology for the quantitative assessment of pruritus. Biomed Instrum Technol 1991;25:400-3.
5. Molenaar HAJ, Oosting J, Jones EA. Improved device for measuring scratching activity in patients with pruritus. Med Biol Eng Comput 1998;36:220-4.
6. Bartholomew TC, Summerfield JA, Billing BH, Lawson AM, Setchell KD. Bile acid profiles of human serum and skin interstitial fluid and their relationship to pruritus studied by gas chromatography-mass spectroscopy. Clin Sci 1982;63:65-73.
7. Bergasa NV, Jones EA. Management of the pruritus of cholestasis. Potential role of opiate antagonists. Am J Gastroenterol 1991;86:1404-12.
8. Cynamon HA, Andes JM, Iafrate PR. Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology 1990;98:1013-6.
9. Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampin with phenobarbitone for treatment of pruritus in primary biliary cirrhosis. Lancet 1989;i:574-6.
10. Ghent CN, Caruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin: results of a double-blind crossover randomized trial. Gastroenterology 1988;94:488-93.
11. Koenigstein H. Experimental study of itch stimuli in animals. Arch Dermatol Syph 1948;57:828-49.
12. Thomas DA, Williams GW, Iwata K, Kenshalo DR Jr, Dubner R. Effects of central administration of opioids on facial scratching in monkeys. Brain Res 1992;585:315-7.
13. De Quincy T. Confessions of an English Opium Eater. London: Penguin, 1971.
14. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacologic Basis of Therapeutics, 8th edn. New York: Pergamon, 1990:485-521.
15. Jones EA, Bergasa NV. The pruritus of cholestasis: From bile acids to opiate agonists. Hepatology 1990;11:884-7.
16. Bergasa NV, Jones EA. The pruritus of cholestasis: Potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995;108:1582-8.
17. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 1988;297:1501-4.
18. Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA. Plasma from patients with the pruritus of cholestasis induces opioid receptor mediated scratching in monkeys. Life Sci 1993;53:1253-7.
19. Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones EA. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992;103:630-5.
20. Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, Jones EA. Central mu-opioid receptors are down-regulated in a rat model of acute cholestasis. J Hepatol 1992;15:220-4.
21. Bergasa NV, Alling DW, Vergalla J, Jones EA. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994;20:85-90.
22. Tao P-L, Law P-Y, Loh HH. Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic morphine treatment. J Pharmacol Exp Ther 1987;240:809-16.
23. Schworer H, Ramadori G. Cholestatischer pruritus - Pathophysiologie und therapie unter besonder berucksichtigung der behandlung mit 5-hydroxy-trypamin-subtype-3-rezeptor-antagonisten. Z Gastroenterol 1995;33:265-74.
24. Kiefel JM, Cooper ML, Bodnar RJ. Serotonin receptor subtype antagonists in the ventral medulla inhibit mesencephalic opiate analgesia. Brain Res 1992;597:331-8.
25. Harsing LG, Yang H-YT. Serotoninergic regulation of hypothalamic metenkephalin content. In: Hannin I, ed. Dynamics of Neurotransmitter Function. New York: Raven, 1984:169-76.
26. Richardson BP. Serotonin and nociception. Ann NY Acad Sci 1990;600:511-20.
27. Larijani GE, Goldberg ME, Rogers KH. Treatment of opioid-induced pruritus with ondansetron: report of four patients. Pharmacotherapy 1996;16:958-60.
28. Crighton IM, Hobbs GJ, Reid MF. Ondansetron for the treatment of pruritus after spinal opioids. Anaesthesia 1996;51:199-200.
29. Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979;115:1366-7.
30. Bergasa NV, Talbot TL, Alling DW, et al. A controlled trial of naloxone infusions for the pruritus of cholestasis. Gastroenterology 1992;102:544-9.
31. Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis: A double-blind randomized controlled trial. Ann Intern Med 1995;123:161-7.
32. Speight TM, Holford NJH, eds. Avery's Drug Treatment, 4th edn. Aukland: Adis International, 1997:1642.
33. Gal TJ, DiFarzio CA, Dixon R. Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther 1986;40:537-42.
34. Michel M, Bolger G, Weissman B-A. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 1985;7:175-7.
35. Dixon R, Howes J, Gentile J, et al. Nalmefene: intravenous safety and kinetics of a new opioid antagonist. Clin Pharmacol Ther 1986;39:49-53.
36. Bergasa NV, Schmitt JM, Talbot TL, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998;27:679-84.
37. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. J Am Acad Dermatol 1999;41:431-4
38. Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Berrolotti M, van Buuren HR. Oral naltrexone for cholestatic pruritus - A double-blind, placebo-controlled study. Gastroenterology 1997;113:1264-9.
39. Mitchell JE. Naltrexone and hepatotoxicity. Lancet 1986;i:1215.
40. Schworer H, Ramadori G. Improvement of cholestatic pruritus by ondansetron. Lancet 1993;341:1277.
41. Schworer H, Ramadori G. Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. Clin Invest 1993;71:659-62.
42. Raderer M, Muller Ch, Scheithauer W. Ondansetron for pruritus due to cholestasis. N Engl J Med 1994;330:1540.
43. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995;61:33-7.
44. Muller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998;10:865-70.
45. Bergasa NV, Sabol SL, Young WS III, Kleiner DE, Jones EA. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995;268:G346-54.
46. Banks WA, Andus KL, Davis TP. Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically useful analogs. Peptides 1992;13:1289-94.
47. Zylicz Z, Krajnik M. Codeine for pruritus in primary biliary cirrhosis. Lancet 1999;353:813.
48. Zylicz Z, Smits C, Zrajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manag 1998;16:121-4.
49. Borgeat A, Wilder-Smith O, Mentha G, Huber O. Propofol and cholestatic pruritus. Am J Gastroenterol 1992;87:672-4.
50. Borgeat A, Wilder-Smith OHG, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993;104:244-7.
51. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone withdrawal. N Engl J Med 1976;294:1104-6.
52. Borgeat A, Wilder-Smith OHG, Saiah M, Rifat K. Subhypnotic doses of propofol relieve pruritus induced by epidural and intrathecal morphine. Anaesthesiology 1992;76:510-2.